Skip to main content Back to Top
Advertisement

6/15/2022

Hydralazine injection

Products Affected - Description

    • Hydralazine injection, American Regent, 20 mg/mL, 1 mL vial, 25 count, NDC 00517-0901-25
    • Hydralazine injection, Fresenius Kabi, 20 mg/mL, 1 mL vial, 25 count, NDC 63323-0614-01
    • Hydralazine injection, Hikma, 20 mg/mL, 1 mL vial, 25 count, NDC 00641-6231-25
    • Hydralazine injection, Mylan Institutional, 20 mg/mL, 1 mL vial, 25 count, NDC 67457-0291-01

Reason for the Shortage

    • Akorn has hydralazine injection available. They are currently not marketing the 25 count size.
    • American Regent did not provide a reason for the shortage.
    • Fresenius Kabi has hydralazine on shortage due to increased demand.
    • Hikma did not provide a reason for the shortage.
    • Mylan has hydralazine injection on shortage due to increased demand.
    • X-Gen is not currently manufacturing hydralazine injection.

Available Products

    • Hydralazine injection, Akorn, 20 mg/mL, 1 mL vial, 10 count, NDC 17478-0934-10

Estimated Resupply Dates

    • American Regent has hydralazine 20 mg/mL 1 mL vials available in limited supply.
    • Mylan Institutional has hydralazine 20 mg/mL 1 mL vials on back order and the company cannot estimate a release date.
    • Fresenius Kabi has hydralazine 20 mg/mL 1 mL vials on back order and the company estimates a release date of early-July 2022.
    • Hikma has hydralazine 20 mg/mL 1 mL vials on allocation.

Updated

Updated June 15, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 4, 2018 by Anthony Trovato, PharmD, BCPS. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.